Advanced search
Publication Cover
Acta Oncologica Volume 53, 2014 - Issue 9
Journal homepage
1,263
Views
7
CrossRef citations to date
0
Altmetric
Letters to the Editor

Treatment with eribulin (halaven) in heavily pre-treated patients with metastatic breast cancer

Maja Lynge RasmussenDepartment of Oncology, Aarhus University Hospital, Aarhus, DenmarkCorrespondence[email protected]
,
Gabor LipositsDepartment of Oncology, Herning Hospital, Denmark
,
Subethini YogendramDepartment of Oncology, Aarhus University Hospital, Aarhus, Denmark
,
Anders Bonde JensenDepartment of Oncology, Aarhus University Hospital, Aarhus, Denmark
,
Søren LinnetDepartment of Oncology, Herning Hospital, Denmark
&
Sven Tyge LangkjerDepartment of Oncology, Aarhus University Hospital, Aarhus, Denmark
Pages 1275-1277 | Received 15 Mar 2014, Accepted 08 Apr 2014, Published online: 20 May 2014

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Anne Sofie Brems-Eskildsen, Kristina Bak Kristoffersen, Søren Linnet, Tamás Lörincz & Sven Tyge Langkjer. (2019) Efficacy and toxicity of eribulin treatment in metastatic breast cancer patients. Acta Oncologica 58:1, pages 119-121.
Read now

Articles from other publishers (6)

Pei-Hsin Chen, Dah-Cherng Yeh, Heng-Hsin Tung & Chin-Yao Lin. (2021) Prognostic and predictive factors of eribulin in patients with heavily pre-treated metastatic breast cancer. Medicine 100:47, pages e27859.
Crossref
Murat Sari & Pınar Saip. (2020) Eribulin monotherapy in heavily pretreated metastatic breast cancer patients in real life. Indian Journal of Cancer 57:1, pages 55.
Crossref
Ornella Garrone, Emanuela Miraglio, Anna Maria Vandone, Paola Vanella, Daniele Lingua & Marco C Merlano. (2017) Eribulin in advanced breast cancer: safety, efficacy and new perspectives. Future Oncology 13:30, pages 2759-2769.
Crossref
Ioannis A. Voutsadakis. (2017) A systematic review and pooled analysis of retrospective series of eribulin in metastatic breast cancer. Anti-Cancer Drugs 28:5, pages 557-564.
Crossref
Erica Quaquarini, Federico Sottotetti, Daniela D’Ambrosio, Alberto Malovini, Stefania Morganti, Arianna Marinello, Lorenzo Pavesi & Mara Frascaroli. (2017) Eribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patients. Future Oncology 13:11s, pages 11-23.
Crossref
Mélodie Dell’Ova, Eléonora De Maio, Séverine Guiu, Lise Roca, Florence Dalenc, Anna Durigova, Frédéric Pinguet, Khedidja Bekhtari, William Jacot & Stéphane Pouderoux. (2015) Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study. BMC Cancer 15:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.